The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MTNB | -58.82% | -96.58% | -49.08% | -98% |
| S&P | +14.5% | +93.32% | +14.09% | +239% |
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.
The company reported disappointing clinical results.
The proposed brand name for its leading pipeline drug got an important nod.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.12M | 48.5% |
| Market Cap | $4.53M | -86.8% |
| Market Cap / Employee | $0.65M | 0.0% |
| Employees | 7 | -78.1% |
| Net Income | -$5.25M | 8.3% |
| EBITDA | -$1.71M | 69.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $6.58M | 54.1% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.71M | -32.5% |
| Short Term Debt | $0.82M | 15.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -109.58% | -31.1% |
| Return On Invested Capital | -96.00% | -40.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$2.02M | 34.9% |
| Operating Free Cash Flow | -$2.02M | 34.9% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.93 | 0.16 | 0.17 | 0.72 | -69.47% |
| Price to Sales | 42.86 | - | |||
| Price to Tangible Book Value | 1.20 | 0.23 | 0.23 | 1.13 | -66.53% |
| Enterprise Value to EBITDA | -2.43 | 0.49 | 0.89 | -0.28 | -94.44% |
| Return on Equity | -108.6% | -180.7% | -192.8% | -146.5% | 50.08% |
| Total Debt | $3.07M | $2.89M | $2.71M | $2.53M | -21.94% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
